LETIM Robustly Predicts Immune Checkpoint Blockade Efficacy for Liver Cancer Patients Using Multiple Immune‐Related Genesets
Through comprehensive analysis of the effects of multiple immune cells on ICB response, LETIM achieved accurate prediction of ICB outcomes in liver cancer. Its cross-cohort applicability and robust predictive performance may support clinical translation to enable precision medicine and maximize patient benefits.
Authors
- Q Liu
- Siqi Tang
- Wenbing Yao
- Hong Tian
- Jiawei Yang
- Xiangdong Gao
- Wenbin Xie
- Zijie Wu
Institutions
- China Pharmaceutical University (CN)
- Chongqing Medical and Pharmaceutical College (CN)
- State Key Laboratory of Natural Medicine
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1111/jgh.70232
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China